Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,624,805

« Back to Dashboard

Details for Patent: 5,624,805

Title: Uses for antibodies which bind to human somatomedin carrier protein subunits
Abstract:This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides, also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps. This invention also relates to DNA molecules encoding human somatomedin carrier protein-like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein-like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins. The DNA molecules, recombinant DNA molecules, hosts, and processes of this invention may be used in the production of polypeptides useful in a variety of therapeutic, diagnostic, and other useful applications.
Inventor(s): Spencer; Emerald M. (San Francisco, CA), Talkington-Verser; Carol (San Rafael, CA)
Assignee: Celtrix Pharmaceuticals, Inc. (Santa Clara, CA)
Filing Date:May 12, 1995
Application Number:08/440,228
Claims:1. A method for measuring the level of unbound somatomedins in human fluids comprising:

contacting an antibody with said human fluids which binds specifically to a carrier protein subunit which:

(a) has the N-terminal amino acid sequence, Gly-Ala-Ser-Ser-Ala-Gly-Leu-Gly-Pro-Val-Val-Arg-R-Glu-Pro-R-Asp-Ala-Arg-Al a-Leu-Ala, wherein R is a cysteine or half-cysteine;

(b) binds insulin-like growth factor 1 (IGF-I); and

(c) has a molecular weight of about 15,000 to 30,000 daltons as determined by sodium dodecyl sulfate gel electrophoresis under reducing conditions to separate somatomedins complexed with carrier protein subunits having the N-terminal amino acid sequence Gly-Ala-Ser-Ser-Ala-Gly-Leu-Gly-Pro-Val-Val-Arg-R-Glu-Pro-R-Asp-Ala-Arg-Al a-Leu-Ala- from the somatomedins not bound to said carrier protein subunits, and

measuring said somatomedins not bound to said carrier protein subunits.

2. The method of claim 1 wherein said somatomedins not bound to said carrier protein subunits are measured by RIA.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.